IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders
July 12, 2023 03:00 ET
|
IRBM
Multi-year drug discovery collaboration to identify small molecule cGAS inhibitors for treating neurodegenerative diseases including Alzheimer’s ROME, July 12, 2023 (GLOBE NEWSWIRE) -- IRBM,...
IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc., Rahway NJ USA
June 22, 2023 16:30 ET
|
IRBM
ROME, June 22, 2023 (GLOBE NEWSWIRE) -- IRBM, an innovative contract research organization, today announced it has signed a new agreement with Merck & Co. Inc., Rahway NJ USA, known as MSD...
IRBM Selected for Participation in National Chemical Biology Consortium
April 04, 2023 03:00 ET
|
IRBM
ROME, April 04, 2023 (GLOBE NEWSWIRE) -- IRBM, a drug discovery and early development research institute and global contract research organization, announces that it is joining the Chemical Biology...
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Josh Bartch, CEO of Mydecine Innovations Group Inc.
January 11, 2022 08:17 ET
|
InvestorBrandNetwork (IBN)
NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment...
Mycotopia Therapies Signs Agreement With Havn Life Sciences For Purchase of Psilocybin SPP
August 25, 2021 08:00 ET
|
Mycotopia Therapies Inc.
MIAMI, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies, Inc. (OTC Pink: TPIA) (the “Company”), a company focused on psychedelic therapies, announced today it has entered into a Psilocybin...
Inotiv Acquires Laboratory Instrumentation for Discovery and Development of Novel Therapies
July 15, 2021 08:33 ET
|
Inotiv, Inc.
WEST LAFAYETTE, Ind., July 15, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Inotiv Acquires Genetic Toxicology Assets from MilliporeSigma’s BioReliance® portfolio
July 12, 2021 08:33 ET
|
Inotiv, Inc.
WEST LAFAYETTE, Ind., July 12, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference
March 08, 2021 08:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and...
Interpace Biosciences Announces CFO Leadership Transition
February 04, 2021 16:42 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has...
CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings
December 14, 2020 08:07 ET
|
Cybin Inc.
--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications-- --Adelia brings a range of technologies related to novel...